Actively Recruiting
Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease
Led by Odense University Hospital · Updated on 2022-11-15
400
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
Sponsors
O
Odense University Hospital
Lead Sponsor
U
University of Southern Denmark
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research investigates how patients with chronic kidney disease (CKD) undergoing hemodialysis (HD) are affected by bloodstream infections, particularly those caused by Staphylococcus aureus. HD patients face a very high risk of death, especially early after infection, largely due to cardiovascular problems and infections like endocarditis. The study aims to understand how HD may weaken the immune response and promote blood clotting that supports bacterial growth, increasing infection risks. The study collects blood samples from four groups: CKD patients on hemodialysis, CKD patients not on dialysis, CKD patients on peritoneal dialysis, and healthy volunteers. Blood plasma is analyzed before and after HD sessions to measure inflammation and coagulation markers. The study compares these levels across groups to explore the effects of HD on immune activity and blood clotting. Participants will provide blood samples at enrollment and during HD sessions. Researchers will measure plasma levels of activated contact system markers, especially cHK, to assess immune and coagulation status. The study focuses on understanding blood changes related to infections and clotting in CKD and dialysis patients. Participation involves blood draws and health assessments, with data collected to improve knowledge about infection risks and immune function in this population.
CONDITIONS
Brief Title
Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Diagnosis of chronic kidney disease
- For hemodialysis group: currently undergoing hemodialysis
- For non-dialysis group: eGFR between less than 15 to 44 and not on dialysis
- For peritoneal dialysis group: currently undergoing peritoneal dialysis
- For healthy volunteers: blood donors aged over 18 years
You will not qualify if you...
- Acute kidney disease
- For non-dialysis group: undergoing hemodialysis or peritoneal dialysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At enrollment
Participants undergo assessments including blood sampling to measure plasma levels related to chronic kidney disease.
1 visit (in-person)
Duration - Up to 9 years
Participants are observed over time to monitor the activation of the contact system and immune system without receiving any intervention.
Visits as per routine clinical care
Trial Site Locations
Total: 1 location
1
Odense University Hospital
Odense, Denmark, 5230
Actively Recruiting
Research Team
K
Katrine Pilely, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here